# A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa

Source: https://onco.cc/trials/nct06091865/  
OnCo record `nct06091865` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Odronextamab, Rituximab, Cyclophosphamide in diffuse large b-cell lymphoma, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT06091865 by Regeneron Pharmaceuticals, with 904 participants planned, started 2023-12-13 and due to reach its primary completion in 2028-03-30. Interventions recorded: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine. Conditions listed: Diffuse Large B-cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06091865
- Phase: 3
- Setting: A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 904

## Sources

- ClinicalTrials.gov NCT06091865: https://clinicaltrials.gov/study/NCT06091865

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Odronextamab](https://onco.cc/drugs/odronextamab/), [Prednisone](https://onco.cc/drugs/prednisone/), [Rituximab](https://onco.cc/drugs/rituximab/), [Vincristine](https://onco.cc/drugs/vincristine/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct06091865.json